Back to News
Market Impact: 0.3
Johnson & Johnson's TREMFYA Shows Improvement In Axial Psoriatic Arthritis
Source: Nasdaq
Healthcare & BiotechProduct Launches
Johnson & Johnson reported positive topline Phase 4 STAR study results for TREMFYA (guselkumab) in adults with active psoriatic arthritis. The treatment improved axial symptoms and reduced MRI-confirmed inflammation, supporting its clinical profile in the immunology portfolio. The update is favorable for J&J's pharmaceutical franchise, although the article provided no detailed efficacy statistics or financial impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.42
Ticker Sentiment
JNJ0.72
More News
- Johnson & Johnson says Tremfya eases spinal pain in Phase 4 psoriatic arthritis study
- Anthropic Goes Big on Compute, Microsoft Rethinks AI
- Wall Street Week | China’s Trade Reckoning, Syracuse’s Second Chance, Humanoids in Healthcare
- Yields keep rising, Novo's tough week, why cat product sales are surging and more in Morning Squawk
- Details on U.S.-China trade negotiations coming Monday, USTR Greer says
- Meta's 'powerful breakout' sets up a unique trading strategy, says Mike Khouw
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: Adding Live MBO Level 3 Data - Liquidity Heatmap, OFI Charts, and More
- AI Software for Buy-Side Teams: Build the Research Stack